Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Multinational Pharma Wants More from China’s Drug Rules

publication date: Dec 18, 2007

After all the hubbub of drug safety and IP protection, China took some major steps in 2007 to reform its regulatory system. In all, China has issued 53 regulations in 2007 that affect drugs, devices and food. But, according to Chen Yang, an attorney from the Beijing office of Sidley Austin, China overlooked three things on multinational pharma’s wish list: defining what constitutes a new chemical entity, assuring confidentiality of submissions for drug regulation, and linking drug approvals to patent protection. More details...



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital